Skip to main content
Top
Published in: Journal of Ovarian Research 1/2013

Open Access 01-12-2013 | Review

Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma

Author: Raoul Orvieto

Published in: Journal of Ovarian Research | Issue 1/2013

Login to get access

Abstract

Ovarian hyperstimulation syndrome (OHSS) is a serious complication of controlled ovarian hyperstimulation (COH). The syndrome almost always presents either after hCG administration in susceptible patients or during early pregnancy. Despite many years of clinical experience, there are no precise methods to completely prevent severe OHSS, except by withholding the ovulation-inducing trigger of hCG. Recently, COH which combining GnRH antagonist co-treatment and GnRH agonist trigger has become a common tool aiming to eliminate severe early OHSS. However, the observed decrease in implantation and pregnancy rates following this approach has encouraged different modifications of luteal support aiming to improve outcome. One of the suggest approach is the 1500 IU hCG luteal rescue, which appears to be a promising protocol, aiming to reduce (rather than eliminating) severe early OHSS, without compromising outcome. In the present paper we discuss the different suggested strategies and offer a strict triage, aimed at eliminating the occurrence of severe OHSS based on several clinical observations, including the role of GnRH-antagonist in COH protocols, the use of different luteal rescue protocols and the ability to transfer embryos in the blastocyst stage.
Appendix
Available only for authorised users
Literature
1.
go back to reference Navot D, Bergh PA, Laufer N: Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992, 58: 249–261.PubMed Navot D, Bergh PA, Laufer N: Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992, 58: 249–261.PubMed
2.
go back to reference Orvieto R, Ben-Rafael Z: Ovarian hyperstimulation syndrome: a new insight into an old enigma. J Soc Gynecol Invest 1998, 5: 110–113. 10.1016/S1071-5576(97)00113-5CrossRef Orvieto R, Ben-Rafael Z: Ovarian hyperstimulation syndrome: a new insight into an old enigma. J Soc Gynecol Invest 1998, 5: 110–113. 10.1016/S1071-5576(97)00113-5CrossRef
3.
go back to reference Kol S: Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004, 81: 1–5.PubMedCrossRef Kol S: Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004, 81: 1–5.PubMedCrossRef
4.
go back to reference Orvieto R: Can we eliminate severe ovarian hyperstimulation syndrome? Hum Reprod 2005, 20: 320–322.PubMedCrossRef Orvieto R: Can we eliminate severe ovarian hyperstimulation syndrome? Hum Reprod 2005, 20: 320–322.PubMedCrossRef
5.
go back to reference Devroey P, Polyzos NP, Blockeel C: An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 2011, 6: 2593–2597.CrossRef Devroey P, Polyzos NP, Blockeel C: An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 2011, 6: 2593–2597.CrossRef
6.
go back to reference Griesinger G, Diedrich K, Devroey P, Kolibianakis EM: GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006, 12: 159–168.PubMedCrossRef Griesinger G, Diedrich K, Devroey P, Kolibianakis EM: GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006, 12: 159–168.PubMedCrossRef
7.
go back to reference Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R: Substituting HCG with GnRH agonist to trigger final follicular maturation–a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 2006, 13: 198–201. 10.1016/S1472-6483(10)60615-3PubMedCrossRef Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R: Substituting HCG with GnRH agonist to trigger final follicular maturation–a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 2006, 13: 198–201. 10.1016/S1472-6483(10)60615-3PubMedCrossRef
8.
go back to reference Kol S, Humaidan P: GnRH agonist triggering: recent developments. Reprod Biomed Online 2013, 26: 226–230. 10.1016/j.rbmo.2012.11.002PubMedCrossRef Kol S, Humaidan P: GnRH agonist triggering: recent developments. Reprod Biomed Online 2013, 26: 226–230. 10.1016/j.rbmo.2012.11.002PubMedCrossRef
9.
go back to reference Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S: Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a 'freeze-all’ strategy: a prospective multicentric study. Fertil Steril 2011, 95: 2029–2033. 10.1016/j.fertnstert.2011.01.163PubMedCrossRef Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S: Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a 'freeze-all’ strategy: a prospective multicentric study. Fertil Steril 2011, 95: 2029–2033. 10.1016/j.fertnstert.2011.01.163PubMedCrossRef
10.
go back to reference Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C: The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study. Fertil Steril 2008, 89: 84–91. 10.1016/j.fertnstert.2007.02.002PubMedCrossRef Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C: The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study. Fertil Steril 2008, 89: 84–91. 10.1016/j.fertnstert.2007.02.002PubMedCrossRef
11.
go back to reference Orvieto R: Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Reprod Biomed Online 2012, 24: 680–681. 10.1016/j.rbmo.2012.03.005PubMedCrossRef Orvieto R: Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Reprod Biomed Online 2012, 24: 680–681. 10.1016/j.rbmo.2012.03.005PubMedCrossRef
12.
go back to reference Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY: 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin- releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010, 93: 847–854. 10.1016/j.fertnstert.2008.12.042PubMedCrossRef Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY: 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin- releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010, 93: 847–854. 10.1016/j.fertnstert.2008.12.042PubMedCrossRef
13.
go back to reference Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM: The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 2012, 24: 134–141. 10.1016/j.rbmo.2011.11.001PubMedCrossRef Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM: The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 2012, 24: 134–141. 10.1016/j.rbmo.2011.11.001PubMedCrossRef
14.
go back to reference Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH: Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013,28(9):2522–2528. 10.1093/humrep/det124PubMedCrossRef Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH: Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013,28(9):2522–2528. 10.1093/humrep/det124PubMedCrossRef
15.
go back to reference Navot D, Bergh PA, Laufer N: The ovarian hyperstimulation syndrome. In Reproductive Endocrinology, Surgery, and Technology. Edited by: Adashi E, Rock JA, Rosenwaks Z. Philadelphia: Lippincott–Raven Publishers; 1996:2215–2232. Navot D, Bergh PA, Laufer N: The ovarian hyperstimulation syndrome. In Reproductive Endocrinology, Surgery, and Technology. Edited by: Adashi E, Rock JA, Rosenwaks Z. Philadelphia: Lippincott–Raven Publishers; 1996:2215–2232.
16.
go back to reference Asch RH, Lo HP, Balmaceda JP, Weckstein LN, Stone SC: Severe ovarian hyperstimulation syndrome in assisted reproductive technology: defnition of high risk groups. Hum Reprod 1991, 6: 1395–1399.PubMed Asch RH, Lo HP, Balmaceda JP, Weckstein LN, Stone SC: Severe ovarian hyperstimulation syndrome in assisted reproductive technology: defnition of high risk groups. Hum Reprod 1991, 6: 1395–1399.PubMed
17.
go back to reference Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P: Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006, 85: 112–120. 10.1016/j.fertnstert.2005.07.1292PubMedCrossRef Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P: Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006, 85: 112–120. 10.1016/j.fertnstert.2005.07.1292PubMedCrossRef
18.
go back to reference Orvieto R, Ben-Rafael Z: Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 1998, 13: 3306–3309. 10.1093/humrep/13.12.3306PubMedCrossRef Orvieto R, Ben-Rafael Z: Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 1998, 13: 3306–3309. 10.1093/humrep/13.12.3306PubMedCrossRef
19.
go back to reference Orvieto R, Achiron A, Ben-Rafael Z, Hagay Z, Achiron R: The possible role of intravenous immunoglobulin in preventing preeclampsia. Med Hypoth 1993, 41: 160–164. 10.1016/0306-9877(93)90063-VCrossRef Orvieto R, Achiron A, Ben-Rafael Z, Hagay Z, Achiron R: The possible role of intravenous immunoglobulin in preventing preeclampsia. Med Hypoth 1993, 41: 160–164. 10.1016/0306-9877(93)90063-VCrossRef
20.
go back to reference Levy T, Orvieto R, Homburg R, Dekel A, Peleg D, Ben-Rafael Z: Severe ovarian hyperstimulation syndrome despite low plasma estrogen levels in a hypogonadotropic hypogonadal patient. Hum Reprod 1996, 11: 1177–1179. 10.1093/oxfordjournals.humrep.a019350PubMedCrossRef Levy T, Orvieto R, Homburg R, Dekel A, Peleg D, Ben-Rafael Z: Severe ovarian hyperstimulation syndrome despite low plasma estrogen levels in a hypogonadotropic hypogonadal patient. Hum Reprod 1996, 11: 1177–1179. 10.1093/oxfordjournals.humrep.a019350PubMedCrossRef
21.
go back to reference Orvieto R: Elimination of ovarian hyperstimulatin syndrome. Fertil Steril 2012, 97: e29. 10.1016/j.fertnstert.2012.03.019PubMedCrossRef Orvieto R: Elimination of ovarian hyperstimulatin syndrome. Fertil Steril 2012, 97: e29. 10.1016/j.fertnstert.2012.03.019PubMedCrossRef
22.
go back to reference Orvieto R: Prediction of OHSS—challenging the estradiol mitos. Hum Reprod 2003, 18: 665–667. 10.1093/humrep/deg166PubMedCrossRef Orvieto R: Prediction of OHSS—challenging the estradiol mitos. Hum Reprod 2003, 18: 665–667. 10.1093/humrep/deg166PubMedCrossRef
23.
go back to reference The Practice Committee of the American Society for Reproductive Medicine (ASRM): Ovarian hyperstimulation syndrome. Fertil Steril 2008, 90: S188-S193. The Practice Committee of the American Society for Reproductive Medicine (ASRM): Ovarian hyperstimulation syndrome. Fertil Steril 2008, 90: S188-S193.
24.
go back to reference Soares SR: Etiology of OHSS and use of dopamine agonists. Fertil Steril 2012, 97: 517–522. 10.1016/j.fertnstert.2011.12.046PubMedCrossRef Soares SR: Etiology of OHSS and use of dopamine agonists. Fertil Steril 2012, 97: 517–522. 10.1016/j.fertnstert.2011.12.046PubMedCrossRef
Metadata
Title
Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma
Author
Raoul Orvieto
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2013
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/1757-2215-6-77

Other articles of this Issue 1/2013

Journal of Ovarian Research 1/2013 Go to the issue